vs

Side-by-side financial comparison of Valero Energy (VLO) and Walgreens Boots Alliance (WBA). Click either name above to swap in a different company.

Walgreens Boots Alliance is the larger business by last-quarter revenue ($39.0B vs $30.4B, roughly 1.3× Valero Energy). Valero Energy runs the higher net margin — 3.7% vs -0.4%, a 4.2% gap on every dollar of revenue. On growth, Walgreens Boots Alliance posted the faster year-over-year revenue change (7.2% vs -1.2%). Over the past eight quarters, Walgreens Boots Alliance's revenue compounded faster (4.9% CAGR vs -2.2%).

Valero Energy Corporation is an American-based fuels producer mostly involved in manufacturing and marketing transportation fuels and other related products. It is headquartered in San Antonio, Texas, United States. Throughout the United States, Canada, and the United Kingdom, the company owns and operates 15 refineries with a combined throughput capacity of approximately 3.2 million barrels per day, two renewable diesel plants that produce approximately 1.

Walgreens Boots Alliance, Inc. (WBA) was an American multinational holding company headquartered in Deerfield, Illinois. The company was formed on December 31, 2014, after Walgreens bought the 55% stake in Alliance Boots that it did not already own. The total price of the acquisition was $4.9 billion in cash and 144.3 million common shares with fair value of $10.7 billion. Walgreens had previously purchased 45% of the company for $4.0 billion and 83.

VLO vs WBA — Head-to-Head

Bigger by revenue
WBA
WBA
1.3× larger
WBA
$39.0B
$30.4B
VLO
Growing faster (revenue YoY)
WBA
WBA
+8.5% gap
WBA
7.2%
-1.2%
VLO
Higher net margin
VLO
VLO
4.2% more per $
VLO
3.7%
-0.4%
WBA
Faster 2-yr revenue CAGR
WBA
WBA
Annualised
WBA
4.9%
-2.2%
VLO

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
VLO
VLO
WBA
WBA
Revenue
$30.4B
$39.0B
Net Profit
$1.1B
$-175.0M
Gross Margin
6.3%
16.7%
Operating Margin
5.2%
0.1%
Net Margin
3.7%
-0.4%
Revenue YoY
-1.2%
7.2%
Net Profit YoY
303.6%
-150.9%
EPS (diluted)
$3.66
$-0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VLO
VLO
WBA
WBA
Q4 25
$30.4B
Q3 25
$32.2B
Q2 25
$29.9B
$39.0B
Q1 25
$30.3B
$38.6B
Q4 24
$30.8B
$39.5B
Q3 24
$32.9B
$37.5B
Q2 24
$34.5B
$36.4B
Q1 24
$31.8B
$37.1B
Net Profit
VLO
VLO
WBA
WBA
Q4 25
$1.1B
Q3 25
$1.1B
Q2 25
$714.0M
$-175.0M
Q1 25
$-595.0M
$-2.9B
Q4 24
$281.0M
$-265.0M
Q3 24
$364.0M
$-3.0B
Q2 24
$880.0M
$344.0M
Q1 24
$1.2B
$-5.9B
Gross Margin
VLO
VLO
WBA
WBA
Q4 25
6.3%
Q3 25
5.5%
Q2 25
4.2%
16.7%
Q1 25
1.7%
18.0%
Q4 24
2.0%
17.2%
Q3 24
2.3%
16.7%
Q2 24
4.2%
17.8%
Q1 24
6.2%
19.0%
Operating Margin
VLO
VLO
WBA
WBA
Q4 25
5.2%
Q3 25
4.7%
Q2 25
3.3%
0.1%
Q1 25
-3.0%
-14.4%
Q4 24
1.1%
-0.6%
Q3 24
1.5%
-2.6%
Q2 24
3.5%
0.3%
Q1 24
5.3%
-35.5%
Net Margin
VLO
VLO
WBA
WBA
Q4 25
3.7%
Q3 25
3.4%
Q2 25
2.4%
-0.4%
Q1 25
-2.0%
-7.4%
Q4 24
0.9%
-0.7%
Q3 24
1.1%
-8.0%
Q2 24
2.6%
0.9%
Q1 24
3.9%
-15.9%
EPS (diluted)
VLO
VLO
WBA
WBA
Q4 25
$3.66
Q3 25
$3.53
Q2 25
$2.28
$-0.20
Q1 25
$-1.90
$-3.30
Q4 24
$0.98
$-0.31
Q3 24
$1.14
$-3.48
Q2 24
$2.71
$0.40
Q1 24
$3.75
$-6.85

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VLO
VLO
WBA
WBA
Cash + ST InvestmentsLiquidity on hand
$4.7B
$830.0M
Total DebtLower is stronger
$9.7B
$7.4B
Stockholders' EquityBook value
$23.7B
$7.2B
Total Assets
$58.0B
$69.4B
Debt / EquityLower = less leverage
0.41×
1.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VLO
VLO
WBA
WBA
Q4 25
$4.7B
Q3 25
$4.8B
Q2 25
$4.5B
$830.0M
Q1 25
$4.6B
$1.1B
Q4 24
$4.7B
$1.2B
Q3 24
$5.2B
$3.1B
Q2 24
$5.2B
$703.0M
Q1 24
$4.9B
$668.0M
Total Debt
VLO
VLO
WBA
WBA
Q4 25
$9.7B
Q3 25
$9.7B
Q2 25
$10.3B
$7.4B
Q1 25
$10.3B
$8.0B
Q4 24
$9.7B
$8.1B
Q3 24
$9.8B
$9.6B
Q2 24
$9.7B
Q1 24
$10.0B
Stockholders' Equity
VLO
VLO
WBA
WBA
Q4 25
$23.7B
Q3 25
$23.8B
Q2 25
$24.1B
$7.2B
Q1 25
$23.5B
$7.1B
Q4 24
$24.5B
$9.9B
Q3 24
$25.3B
$10.4B
Q2 24
$25.4B
$13.6B
Q1 24
$26.1B
$13.5B
Total Assets
VLO
VLO
WBA
WBA
Q4 25
$58.0B
Q3 25
$58.6B
Q2 25
$59.4B
$69.4B
Q1 25
$59.2B
$70.2B
Q4 24
$60.1B
$78.5B
Q3 24
$60.4B
$81.0B
Q2 24
$63.6B
$83.0B
Q1 24
$62.6B
$84.2B
Debt / Equity
VLO
VLO
WBA
WBA
Q4 25
0.41×
Q3 25
0.41×
Q2 25
0.43×
1.03×
Q1 25
0.44×
1.13×
Q4 24
0.40×
0.81×
Q3 24
0.39×
0.92×
Q2 24
0.38×
Q1 24
0.39×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VLO
VLO
WBA
WBA
Operating Cash FlowLast quarter
$2.1B
$584.0M
Free Cash FlowOCF − Capex
$336.0M
FCF MarginFCF / Revenue
0.9%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
1.81×
TTM Free Cash FlowTrailing 4 quarters
$580.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VLO
VLO
WBA
WBA
Q4 25
$2.1B
Q3 25
$1.9B
Q2 25
$936.0M
$584.0M
Q1 25
$952.0M
$-199.0M
Q4 24
$1.1B
$-140.0M
Q3 24
$1.3B
$1.3B
Q2 24
$2.5B
$604.0M
Q1 24
$1.8B
$-637.0M
Free Cash Flow
VLO
VLO
WBA
WBA
Q4 25
Q3 25
$1.5B
Q2 25
$529.0M
$336.0M
Q1 25
$293.0M
$-418.0M
Q4 24
$523.0M
$-424.0M
Q3 24
$866.0M
$1.1B
Q2 24
$2.1B
$327.0M
Q1 24
$1.2B
$-989.0M
FCF Margin
VLO
VLO
WBA
WBA
Q4 25
Q3 25
4.6%
Q2 25
1.8%
0.9%
Q1 25
1.0%
-1.1%
Q4 24
1.7%
-1.1%
Q3 24
2.6%
2.9%
Q2 24
5.9%
0.9%
Q1 24
3.7%
-2.7%
Capex Intensity
VLO
VLO
WBA
WBA
Q4 25
Q3 25
1.3%
Q2 25
1.4%
0.6%
Q1 25
2.2%
0.6%
Q4 24
1.8%
0.7%
Q3 24
1.3%
0.7%
Q2 24
1.2%
0.8%
Q1 24
2.1%
1.0%
Cash Conversion
VLO
VLO
WBA
WBA
Q4 25
1.81×
Q3 25
1.72×
Q2 25
1.31×
Q1 25
Q4 24
3.81×
Q3 24
3.56×
Q2 24
2.81×
1.76×
Q1 24
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

VLO
VLO

Distillates$14.3B47%
Gasoline And Blendstocks$12.5B41%
Manufactured Product Other$1.8B6%
Ethanol Product$784.0M3%
Renewable Diesel Product$589.0M2%
Distillers Grains$194.0M1%
Neat SAF$118.0M0%
Renewable Naphtha Product$24.0M0%

WBA
WBA

Pharmacy$24.4B63%
Retail$6.3B16%
International Reportable Segment$6.2B16%
US Healthcare$2.1B5%

Related Comparisons